Research Progress on the Role and Mechanism of IL-37 in Liver Diseases

Baoyi Jiang; Yulin Zhou; Yanting Liu; Siqi He; Baojian Liao; Tieli Peng; Leyi Yao; Ling Qi

doi:10.1055/a-2153-8836

Seminars in Liver Disease, Table of Contents

CC BY-NC-ND 4.0 · Semin Liver Dis 2023; 43(03): 336-350
DOI: 10.1055/a-2153-8836

Review Article

Research Progress on the Role and Mechanism of IL-37 in Liver Diseases

Baoyi Jiang

¹Institute of Digestive Disease, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital, Qingyuan, China

,

Yulin Zhou

²Department of Clinical Laboratory, Shunde New Rongqi Hospital, Foshan, China

,

Yanting Liu

¹Institute of Digestive Disease, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital, Qingyuan, China

,

Siqi He

¹Institute of Digestive Disease, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital, Qingyuan, China

,

Baojian Liao

¹Institute of Digestive Disease, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital, Qingyuan, China

,

Tieli Peng

¹Institute of Digestive Disease, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital, Qingyuan, China

,

Leyi Yao

¹Institute of Digestive Disease, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital, Qingyuan, China

,

Ling Qi

¹Institute of Digestive Disease, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital, Qingyuan, China

› Author Affiliations

Abstract

Cytokines are important components of the immune system that can predict or influence the development of liver diseases. IL-37, a new member of the IL-1 cytokine family, exerts potent anti-inflammatory and immunosuppressive effects inside and outside cells. IL-37 expression differs before and after liver lesions, suggesting that it is associated with liver disease; however, its mechanism of action remains unclear. This article mainly reviews the biological characteristics of IL-37, which inhibits hepatitis, liver injury, and liver fibrosis by inhibiting inflammation, and inhibits the development of hepatocellular carcinoma (HCC) by regulating the immune microenvironment. Based on additional evidence, combining IL-37 with liver disease markers for diagnosis and treatment can achieve more significant effects, suggesting that IL-37 can be developed into a powerful tool for the clinical adjuvant treatment of liver diseases, especially HCC.

Keywords

IL-37 - hepatitis - liver injury - liver fibrosis - HCC

Full Text

References

References
1 Wang FS, Fan JG, Zhang Z, Gao B, Wang HY. The global burden of liver disease: the major impact of China. Hepatology 2014; 60 (06) 2099-2108
2 Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol 2019; 16 (10) 589-604
3 Wang H, Lu Z, Zhao X. Tumorigenesis, diagnosis, and therapeutic potential of exosomes in liver cancer. J Hematol Oncol 2019; 12 (01) 133
4 Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet 2018; 391 (10127): 1301-1314
5 Yang YM, Kim SY, Seki E. Inflammation and liver cancer: molecular mechanisms and therapeutic targets. Semin Liver Dis 2019; 39 (01) 26-42
6 He Y, Hwang S, Ahmed YA. et al. Immunopathobiology and therapeutic targets related to cytokines in liver diseases. Cell Mol Immunol 2021; 18 (01) 18-37
7 Rico Montanari N, Anugwom CM, Boonstra A, Debes JD. The role of cytokines in the different stages of hepatocellular carcinoma. Cancers (Basel) 2021; 13 (19) 13
8 Catalan-Dibene J, McIntyre LL, Zlotnik A. Interleukin 30 to interleukin 40. J Interferon Cytokine Res 2018; 38 (10) 423-439
9 Kumar S, McDonnell PC, Lehr R. et al. Identification and initial characterization of four novel members of the interleukin-1 family. J Biol Chem 2000; 275 (14) 10308-10314
10 Kumar S, Hanning CR, Brigham-Burke MR. et al. Interleukin-1F7B (IL-1H4/IL-1F7) is processed by caspase-1 and mature IL-1F7B binds to the IL-18 receptor but does not induce IFN-gamma production. Cytokine 2002; 18 (02) 61-71
11 Nold MF, Nold-Petry CA, Zepp JA, Palmer BE, Bufler P, Dinarello CA. IL-37 is a fundamental inhibitor of innate immunity. Nat Immunol 2010; 11 (11) 1014-1022
12 Gao B. Hepatoprotective and anti-inflammatory cytokines in alcoholic liver disease. J Gastroenterol Hepatol 2012; 27 (Suppl. 02) 89-93
13 Jia H, Liu J, Han B. Reviews of interleukin-37: functions, receptors, and roles in diseases. BioMed Res Int 2018; 3058640
14 Boraschi D, Lucchesi D, Hainzl S. et al. IL-37: a new anti-inflammatory cytokine of the IL-1 family. Eur Cytokine Netw 2011; 22 (03) 127-147
15 Keller M, Rüegg A, Werner S, Beer HD. Active caspase-1 is a regulator of unconventional protein secretion. Cell 2008; 132 (05) 818-831
16 Gritsenko A, Díaz-Pino R, López-Castejón G. NLRP3 inflammasome triggers interleukin-37 release from human monocytes. Eur J Immunol 2022; 52 (07) 1141-1157
17 Cavalli G, Dinarello CA. Suppression of inflammation and acquired immunity by IL-37. Immunol Rev 2018; 281 (01) 179-190
18 Gao W, Kumar S, Lotze MT, Hanning C, Robbins PD, Gambotto A. Innate immunity mediated by the cytokine IL-1 homologue 4 (IL-1H4/IL-1F7) induces IL-12-dependent adaptive and profound antitumor immunity. J Immunol 2003; 170 (01) 107-113
19 Bufler P, Gamboni-Robertson F, Azam T, Kim SH, Dinarello CA. Interleukin-1 homologues IL-1F7b and IL-18 contain functional mRNA instability elements within the coding region responsive to lipopolysaccharide. Biochem J 2004; 381 (Pt 2): 503-510
20 Rudloff I, Cho SX, Lao JC. et al. Monocytes and dendritic cells are the primary sources of interleukin 37 in human immune cells. J Leukoc Biol 2017; 101 (04) 901-911
21 Hong JT, Son DJ, Lee CK, Yoon DY, Lee DH, Park MH. Interleukin 32, inflammation and cancer. Pharmacol Ther 2017; 174: 127-137
22 Del Campo JA, Gallego P, Grande L. Role of inflammatory response in liver diseases: therapeutic strategies. World J Hepatol 2018; 10 (01) 1-7
23 Bulau AM, Fink M, Maucksch C. et al. In vivo expression of interleukin-37 reduces local and systemic inflammation in concanavalin A-induced hepatitis. ScientificWorldJournal 2011; 11: 2480-2490
24 Sharaf N, Nicklin MJ, di Giovine FS. Long-range DNA interactions at the IL-1/IL-36/IL-37 gene cluster (2q13) are induced by activation of monocytes. Cytokine 2014; 68 (01) 16-22
25 Abulkhir A, Samarani S, Amre D. et al. A protective role of IL-37 in cancer: a new hope for cancer patients. J Leukoc Biol 2017; 101 (02) 395-406
26 Bufler P, Azam T, Gamboni-Robertson F. et al. A complex of the IL-1 homologue IL-1F7b and IL-18-binding protein reduces IL-18 activity. Proc Natl Acad Sci U S A 2002; 99 (21) 13723-13728
27 Tsutsumi N, Kimura T, Arita K. et al. The structural basis for receptor recognition of human interleukin-18. Nat Commun 2014; 5: 5340
28 Schröder A, Lunding LP, Zissler UM. et al. IL-37 regulates allergic inflammation by counterbalancing pro-inflammatory IL-1 and IL-33. Allergy 2022; 77 (03) 856-869
29 Mariotti FR, Supino D, Landolina N. et al. IL-1R8: a molecular brake of anti-tumor and anti-viral activity of NK cells and ILC. Semin Immunol 2023; 66: 101712
30 Nold-Petry CA, Lo CY, Rudloff I. et al. IL-37 requires the receptors IL-18Rα and IL-1R8 (SIGIRR) to carry out its multifaceted anti-inflammatory program upon innate signal transduction. Nat Immunol 2015; 16 (04) 354-365
31 Harms RZ, Creer AJ, Lorenzo-Arteaga KM, Ostlund KR, Sarvetnick NE. Interleukin (IL)-18 binding protein deficiency disrupts natural killer cell maturation and diminishes circulating IL-18. Front Immunol 2017; 8: 1020
32 Allam G, Gaber AM, Othman SI, Abdel-Moneim A. The potential role of interleukin-37 in infectious diseases. Int Rev Immunol 2020; 39 (01) 3-10
33 Kuipery A, Gehring AJ, Isogawa M. Mechanisms of HBV immune evasion. Antiviral Res 2020; 179: 104816
34 Fisicaro P, Barili V, Rossi M. et al. Pathogenetic mechanisms of T cell dysfunction in chronic HBV infection and related therapeutic approaches. Front Immunol 2020; 11: 849
35 Robinson MW, Harmon C, O'Farrelly C. Liver immunology and its role in inflammation and homeostasis. Cell Mol Immunol 2016; 13 (03) 267-276
36 Li C, Ji H, Cai Y. et al. Serum interleukin-37 concentrations and HBeAg seroconversion in chronic HBV patients during telbivudine treatment. J Interferon Cytokine Res 2013; 33 (10) 612-618
37 Zhong S, Zhang T, Tang L, Li Y. Cytokines and chemokines in HBV infection. Front Mol Biosci 2021; 8: 805625
38 Sakai N, Van Sweringen HL, Belizaire RM. et al. Interleukin-37 reduces liver inflammatory injury via effects on hepatocytes and non-parenchymal cells. J Gastroenterol Hepatol 2012; 27 (10) 1609-1616
39 Feng XX, Chi G, Wang H. et al. IL-37 suppresses the sustained hepatic IFN-γ/TNF-α production and T cell-dependent liver injury. Int Immunopharmacol 2019; 69: 184-193
40 Lin SJ, Shu PY, Chang C, Ng AK, Hu CP. IL-4 suppresses the expression and the replication of hepatitis B virus in the hepatocellular carcinoma cell line Hep3B. J Immunol 2003; 171 (09) 4708-4716
41 Yao Y, Li J, Lu Z. et al. Proteomic analysis of the interleukin-4 (IL-4) response in hepatitis B virus-positive human hepatocelluar carcinoma cell line HepG2.2.15. Electrophoresis 2011; 32 (15) 2004-2012
42 Palumbo GA, Scisciani C, Pediconi N. et al. Correction: IL6 inhibits HBV transcription by targeting the epigenetic control of the nuclear cccDNA minichromosome. PLoS One 2015; 10 (12) e0145555
43 Chang TS, Wu YC, Chi CC. et al. Activation of IL6/IGFIR confers poor prognosis of HBV-related hepatocellular carcinoma through induction of OCT4/NANOG expression. Clin Cancer Res 2015; 21 (01) 201-210
44 Zhou X, Yang F, Yang Y. et al. HBV facilitated hepatocellular carcinoma cells proliferation by up-regulating angiogenin expression through IL-6. Cell Physiol Biochem 2018; 46 (02) 461-470
45 Wang B, Zhao XP, Fan YC, Zhang JJ, Zhao J, Wang K. IL-17A but not IL-22 suppresses the replication of hepatitis B virus mediated by over-expression of MxA and OAS mRNA in the HepG2.2.15 cell line. Antiviral Res 2013; 97 (03) 285-292
46 Xiong SQ, Lin BL, Gao X, Tang H, Wu CY. IL-12 promotes HBV-specific central memory CD8+ T cell responses by PBMCs from chronic hepatitis B virus carriers. Int Immunopharmacol 2007; 7 (05) 578-587
47 Wu JF, Hsu HY, Chiu YC, Chen HL, Ni YH, Chang MH. The effects of cytokines on spontaneous hepatitis B surface antigen seroconversion in chronic hepatitis B virus infection. J Immunol 2015; 194 (02) 690-696
48 Zeng Z, Kong X, Li F, Wei H, Sun R, Tian Z. IL-12-based vaccination therapy reverses liver-induced systemic tolerance in a mouse model of hepatitis B virus carrier. J Immunol 2013; 191 (08) 4184-4193
49 Carreño V, Zeuzem S, Hopf U. et al. A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis B. J Hepatol 2000; 32 (02) 317-324
50 Wang H, Luo H, Wan X. et al. TNF-α/IFN-γ profile of HBV-specific CD4 T cells is associated with liver damage and viral clearance in chronic HBV infection. J Hepatol 2020; 72 (01) 45-56
51 Xia Y, Cheng X, Li Y, Valdez K, Chen W, Liang TJ. Hepatitis B virus deregulates the cell cycle to promote viral replication and a premalignant phenotype. J Virol 2018; 92 (19) 92
52 Liu R, Tang C, Shen A. et al. IL-37 suppresses hepatocellular carcinoma growth by converting pSmad3 signaling from JNK/pSmad3L/c-Myc oncogenic signaling to pSmad3C/P21 tumor-suppressive signaling. Oncotarget 2016; 7 (51) 85079-85096
53 Liu Q, Zhou Q, Wang M, Pang B. Interleukin-37 suppresses the cytotoxicity of hepatitis B virus peptides-induced CD8+ T cells in patients with acute hepatitis B. Bosn J Basic Med Sci 2023; 23 (03) 527-534
54 Al-Anazi MR, Matou-Nasri S, Al-Qahtani AA. et al. Association between IL-37 gene polymorphisms and risk of HBV-related liver disease in a Saudi Arabian population. Sci Rep 2019; 9 (01) 7123
55 Wong MCS, Huang JLW, George J. et al. The changing epidemiology of liver diseases in the Asia-Pacific region. Nat Rev Gastroenterol Hepatol 2019; 16 (01) 57-73
56 Saraceni C, Birk J. A review of hepatitis B virus and hepatitis C virus immunopathogenesis. J Clin Transl Hepatol 2021; 9 (03) 409-418
57 Heydtmann M, Shields P, McCaughan G, Adams D. Cytokines and chemokines in the immune response to hepatitis C infection. Curr Opin Infect Dis 2001; 14 (03) 279-287
58 Ding SX, Ma JB, Hu YR, Hu AR, Shen Q, Gao GS. Outcomes of interferon/ribavirin therapy in patients with HCV defined by expression of plasma soluble human leukocyte antigen-G but not IL-37. Med Sci Monit 2016; 22: 1398-1402
59 Wen Y, Lambrecht J, Ju C, Tacke F. Hepatic macrophages in liver homeostasis and diseases-diversity, plasticity and therapeutic opportunities. Cell Mol Immunol 2021; 18 (01) 45-56
60 Roberts RA, Ganey PE, Ju C, Kamendulis LM, Rusyn I, Klaunig JE. Role of the Kupffer cell in mediating hepatic toxicity and carcinogenesis. Toxicol Sci 2007; 96 (01) 2-15
61 Xu Z, Li K, Pan X, Tan J, Li Y, Li M. Protective effects of interleukin-37 expression against acetaminophen-induced hepatotoxicity in mice. Evid Based Complement Alternat Med 2022; 6468299
62 Li G, Kong D, Qin Y. et al. IL-37 overexpression enhances the therapeutic effect of endometrial regenerative cells in concanavalin A-induced hepatitis. Cytotherapy 2021; 23 (07) 617-626
63 Zhou P, Li Q, Su S. et al. Interleukin 37 suppresses M1 macrophage Polarization through inhibition of the Notch1 and nuclear factor kappa B pathways. Front Cell Dev Biol 2020; 8: 56
64 Liew PX, Kubes P. The neutrophil's role during health and disease. Physiol Rev 2019; 99 (02) 1223-1248
65 Wang Y, Liu Y. Neutrophil-induced liver injury and interactions between neutrophils and liver sinusoidal endothelial cells. Inflammation 2021; 44 (04) 1246-1262
66 Amulic B, Cazalet C, Hayes GL, Metzler KD, Zychlinsky A. Neutrophil function: from mechanisms to disease. Annu Rev Immunol 2012; 30: 459-489
67 Seitz HK, Bataller R, Cortez-Pinto H. et al. Alcoholic liver disease. Nat Rev Dis Primers 2018; 4 (01) 16
68 Grabherr F, Grander C, Adolph TE. et al. Ethanol-mediated suppression of IL-37 licenses alcoholic liver disease. Liver Int 2018; 38 (06) 1095-1101
69 Schuppan D, Kim YO. Evolving therapies for liver fibrosis. J Clin Invest 2013; 123 (05) 1887-1901
70 Higashi T, Friedman SL, Hoshida Y. Hepatic stellate cells as key target in liver fibrosis. Adv Drug Deliv Rev 2017; 121: 27-42
71 Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115 (02) 209-218
72 Lindquist JN, Marzluff WF, Stefanovic B. Fibrogenesis. III. Posttranscriptional regulation of type I collagen. Am J Physiol Gastrointest Liver Physiol 2000; 279 (03) G471-G476
73 Yoshida K, Matsuzaki K, Mori S. et al. Transforming growth factor-beta and platelet-derived growth factor signal via c-Jun N-terminal kinase-dependent Smad2/3 phosphorylation in rat hepatic stellate cells after acute liver injury. Am J Pathol 2005; 166 (04) 1029-1039
74 Kluwe J, Pradere JP, Gwak GY. et al. Modulation of hepatic fibrosis by c-Jun-N-terminal kinase inhibition. Gastroenterology 2010; 138 (01) 347-359
75 Dooley S, ten Dijke P. TGF-β in progression of liver disease. Cell Tissue Res 2012; 347 (01) 245-256
76 Matsuzaki K. Smad phospho-isoforms direct context-dependent TGF-β signaling. Cytokine Growth Factor Rev 2013; 24 (04) 385-399
77 Matsuzaki K, Murata M, Yoshida K. et al. Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma. Hepatology 2007; 46 (01) 48-57
78 Mountford S, Effenberger M, Noll-Puchta H. et al. Modulation of liver inflammation and fibrosis by interleukin-37. Front Immunol 2021; 12: 603649
79 Griessmair L, Pirringer L, Mountford S. et al. Expression of IL-37 correlates with immune cell infiltrate and fibrosis in pediatric autoimmune liver diseases. J Pediatr Gastroenterol Nutr 2022; 74 (06) 742-749
80 Sung H, Ferlay J, Siegel RL. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71 (03) 209-249
81 Wong MC, Jiang JY, Goggins WB. et al. International incidence and mortality trends of liver cancer: a global profile. Sci Rep 2017; 7: 45846
82 Chen J, Gingold JA, Su X. Immunomodulatory TGF-β signaling in hepatocellular carcinoma. Trends Mol Med 2019; 25 (11) 1010-1023
83 Xu J, Lin H, Wu G, Zhu M, Li M. IL-6/STAT3 is a promising therapeutic target for hepatocellular carcinoma. Front Oncol 2021; 11: 760971
84 Khemlina G, Ikeda S, Kurzrock R. The biology of hepatocellular carcinoma: implications for genomic and immune therapies. Mol Cancer 2017; 16 (01) 149
85 Dimri M, Satyanarayana A. Molecular signaling pathways and therapeutic targets in hepatocellular carcinoma. Cancers (Basel) 2020; 12 (02) 12
86 Budhu A, Wang XW. The role of cytokines in hepatocellular carcinoma. J Leukoc Biol 2006; 80 (06) 1197-1213
87 Zhao JJ, Pan QZ, Pan K. et al. Interleukin-37 mediates the antitumor activity in hepatocellular carcinoma: role for CD57+ NK cells. Sci Rep 2014; 4: 5177
88 Mei Y, Zhu Y, Teo HY. et al. The indirect antiangiogenic effect of IL-37 in the tumor microenvironment. J Leukoc Biol 2020; 107 (05) 783-796
89 Ding VA, Zhu Z, Xiao H, Wakefield MR, Bai Q, Fang Y. The role of IL-37 in cancer. Med Oncol 2016; 33 (07) 68
90 Johnson DE, O'Keefe RA, Grandis JR. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol 2018; 15 (04) 234-248
91 Pan T, Zhang F, Li F. et al. Shikonin blocks human lung adenocarcinoma cell migration and invasion in the inflammatory microenvironment via the IL–6/STAT3 signaling pathway. Oncol Rep 2020; 44 (03) 1049-1063
92 Won C, Kim BH, Yi EH. et al. Signal transducer and activator of transcription 3-mediated CD133 up-regulation contributes to promotion of hepatocellular carcinoma. Hepatology 2015; 62 (04) 1160-1173
93 Wu J, Zhang J, Shen B. et al. Long noncoding RNA lncTCF7, induced by IL-6/STAT3 transactivation, promotes hepatocellular carcinoma aggressiveness through epithelial-mesenchymal transition. J Exp Clin Cancer Res 2015; 34: 116
94 Kao JT, Feng CL, Yu CJ. et al. IL-6, through p-STAT3 rather than p-STAT1, activates hepatocarcinogenesis and affects survival of hepatocellular carcinoma patients: a cohort study. BMC Gastroenterol 2015; 15: 50
95 Pu XY, Zheng DF, Shen A. et al. IL-37b suppresses epithelial mesenchymal transition in hepatocellular carcinoma by inhibiting IL-6/STAT3 signaling. Hepatobiliary Pancreat Dis Int 2018; 17 (05) 408-415
96 Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol 2012; 30 (07) 658-670
97 Zhang Z, Zhang J, Zhang Y, Xing J, Yu Z. Vaccinia virus expressing IL-37 promotes antitumor immune responses in hepatocellular carcinoma. Cell Biochem Funct 2019; 37 (08) 618-624
98 Zhang Z, Zhang J, He P, Han J, Sun C. Interleukin-37 suppresses hepatocellular carcinoma growth through inhibiting M2 polarization of tumor-associated macrophages. Mol Immunol 2020; 122: 13-20
99 Dang J, He Z, Cui X. et al. The role of IL-37 and IL-38 in colorectal cancer. Front Med (Lausanne) 2022; 9: 811025
100 Macias MJ, Martin-Malpartida P, Massagué J. Structural determinants of Smad function in TGF-β signaling. Trends Biochem Sci 2015; 40 (06) 296-308
101 Budi EH, Duan D, Derynck R. Transforming growth factor-β receptors and Smads: regulatory complexity and functional versatility. Trends Cell Biol 2017; 27 (09) 658-672
102 Wu MZ, Yuan YC, Huang BY. et al. Identification of a TGF-β/SMAD/lnc-UTGF positive feedback loop and its role in hepatoma metastasis. Signal Transduct Target Ther 2021; 6 (01) 395
103 Chen J, Zaidi S, Rao S. et al. Analysis of genomes and transcriptomes of hepatocellular carcinomas identifies mutations and gene expression changes in the transforming growth factor-β pathway. Gastroenterology 2018; 154 (01) 195-210
104 Gupta DK, Singh N, Sahu DK. TGF-β mediated crosstalk between malignant hepatocyte and tumor microenvironment in hepatocellular carcinoma. Cancer Growth Metastasis 2014; 7: 1-8
105 Achyut BR, Yang L. Transforming growth factor-β in the gastrointestinal and hepatic tumor microenvironment. Gastroenterology 2011; 141 (04) 1167-1178
106 Fabregat I, Caballero-Díaz D. Transforming growth factor-β-induced cell plasticity in liver fibrosis and hepatocarcinogenesis. Front Oncol 2018; 8: 357
107 Dituri F, Mancarella S, Cigliano A, Chieti A, Giannelli G. TGF-β as multifaceted orchestrator in HCC progression: signaling, EMT, immune microenvironment, and novel therapeutic perspectives. Semin Liver Dis 2019; 39 (01) 53-69
108 Coulouarn C, Factor VM, Thorgeirsson SS. Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer. Hepatology 2008; 47 (06) 2059-2067
109 Gough NR, Xiang X, Mishra L. TGF-β signaling in liver, pancreas, and gastrointestinal diseases and cancer. Gastroenterology 2021; 161 (02) 434-452.e15
110 Fabregat I, Moreno-Càceres J, Sánchez A. et al; IT-LIVER Consortium. TGF-β signalling and liver disease. FEBS J 2016; 283 (12) 2219-2232
111 Tu S, Huang W, Huang C, Luo Z, Yan X. Contextual regulation of TGF-β signaling in liver cancer. Cells 2019; 8 (10) 8
112 Reichl P, Dengler M, van Zijl F. et al. Axl activates autocrine transforming growth factor-β signaling in hepatocellular carcinoma. Hepatology 2015; 61 (03) 930-941
113 Qin G, Luo M, Chen J. et al. Reciprocal activation between MMP-8 and TGF-β1 stimulates EMT and malignant progression of hepatocellular carcinoma. Cancer Lett 2016; 374 (01) 85-95
114 Yu W, Huang C, Wang Q. et al. MEF2 transcription factors promotes EMT and invasiveness of hepatocellular carcinoma through TGF-β1 autoregulation circuitry. Tumour Biol 2014; 35 (11) 10943-10951
115 Ferrín G, Guerrero M, Amado V, Rodríguez-Perálvarez M, De la Mata M. Activation of mTOR signaling pathway in hepatocellular carcinoma. Int J Mol Sci 2020; 21 (04) 21
116 Yang H, Ni HM, Ding WX. The double-edged sword of MTOR in autophagy deficiency induced-liver injury and tumorigenesis. Autophagy 2019; 15 (09) 1671-1673
117 Huang F, Wang BR, Wang YG. Role of autophagy in tumorigenesis, metastasis, targeted therapy and drug resistance of hepatocellular carcinoma. World J Gastroenterol 2018; 24 (41) 4643-4651
118 Qu X, Yu J, Bhagat G. et al. Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J Clin Invest 2003; 112 (12) 1809-1820
119 Karantza-Wadsworth V, Patel S, Kravchuk O. et al. Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis. Genes Dev 2007; 21 (13) 1621-1635
120 Rabinowitz JD, White E. Autophagy and metabolism. Science 2010; 330 (6009) 1344-1348
121 Liu EY, Ryan KM. Autophagy and cancer – issues we need to digest. J Cell Sci 2012; 125 (Pt 10): 2349-2358
122 Liu K, Lee J, Ou JJ. Autophagy and mitophagy in hepatocarcinogenesis. Mol Cell Oncol 2018; 5 (02) e1405142
123 Yun CW, Lee SH. The roles of autophagy in cancer. Int J Mol Sci 2018; 19 (11) 19
124 Li TT, Zhu D, Mou T. et al. IL-37 induces autophagy in hepatocellular carcinoma cells by inhibiting the PI3K/AKT/mTOR pathway. Mol Immunol 2017; 87: 132-140
125 Ringelhan M, Pfister D, O'Connor T, Pikarsky E, Heikenwalder M. The immunology of hepatocellular carcinoma. Nat Immunol 2018; 19 (03) 222-232
126 Rizvi S, Wang J, El-Khoueiry AB. Liver cancer immunity. Hepatology 2021; 73 (Suppl. 01) 86-103
127 Wu X, Gu Z, Chen Y. et al. Application of PD-1 blockade in cancer immunotherapy. Comput Struct Biotechnol J 2019; 17: 661-674
128 Mizukoshi E, Kaneko S. Immune cell therapy for hepatocellular carcinoma. J Hematol Oncol 2019; 12 (01) 52
129 Han C, Jiang Y, Wang Z, Wang H. Natural killer cells involved in tumour immune escape of hepatocellular carcinoma. Int Immunopharmacol 2019; 73: 10-16
130 Liu Y, Zhao JJ, Zhou ZQ. et al. IL-37 induces anti-tumor immunity by indirectly promoting dendritic cell recruitment and activation in hepatocellular carcinoma. Cancer Manag Res 2019; 11: 6691-6702
131 Huo J, Hu J, Liu G, Cui Y, Ju Y. Elevated serum interleukin-37 level is a predictive biomarker of poor prognosis in epithelial ovarian cancer patients. Arch Gynecol Obstet 2017; 295 (02) 459-465
132 Wang Z, Zeng FL, Hu YW. et al. Interleukin-37 promotes colitis-associated carcinogenesis via SIGIRR-mediated cytotoxic T cells dysfunction. Signal Transduct Target Ther 2022; 7 (01) 19
133 Osborne DG, Domenico J, Luo Y. et al. Interleukin-37 is highly expressed in regulatory T cells of melanoma patients and enhanced by melanoma cell secretome. Mol Carcinog 2019; 58 (09) 1670-1679
134 Bodzin AS, Busuttil RW. Hepatocellular carcinoma: advances in diagnosis, management, and long term outcome. World J Hepatol 2015; 7 (09) 1157-1167
135 Guo H, Li P, Su L. et al. Low expression of IL-37 protein is correlated with high Oct4 protein expression in hepatocellular carcinoma. Gene 2020; 737: 144445
136 Li P, Guo H, Wu K. et al. Decreased IL-37 expression in hepatocellular carcinoma tissues and liver cancer cell lines. Oncol Lett 2020; 19 (04) 2639-2648
137 Yang Z, Zhang Q, Xu K. et al. Combined therapy with cytokine-induced killer cells and oncolytic adenovirus expressing IL-12 induce enhanced antitumor activity in liver tumor model. PLoS One 2012; 7 (09) e44802